A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

NCT04184895 | Active Not Recruiting Phase 1

• 3 other identifiers: 2390-CL-00012018-004678-832022-500660-35-00
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of multiple ascending intradermal doses of ASP2390 in adult male and female participants allergic to house dust mites (HDM). This study will also evaluate the effect of multiple ascending intradermal doses of ASP2390 on HDM-specific immunoglobulin G subclass 4 (IgG4) levels in adult male and female participants allergic to HDM.

Conditions

Allergic to House Dust Mites

Keywords

Tolerability; HDM; ASP2390; Safety

Outcome Measures

Primary Outcomes (7)

• Number of participants with Adverse Events (AEs)

  AEs will be coded using medical dictionary for regulatory activities(MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a medicinal product whether or not considered related to the medicinal product. Confirmed and suspected SARS-CoV-2 infection and COVID-19 will be recorded as an AE. An AE is considered serious if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by an AE); or other medically important events.

  Up to week 63

• Number of participants with laboratory value abnormalities and/or AEs

  Number of participants with potentially clinically significant laboratory values.

  Up to week 63

• Number of participants with vital sign abnormalities and/or AEs

  Number of participants with potentially clinically significant vital sign values.

  Up to week 63

• Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs

  Routine 12-lead ECGs will be taken after the participant has been resting in the supine position for at least 5 minutes. Routine 12-lead ECGs will be taken in triplicate.

  Up to week 63

• Number of participants with subcutaneous immunotherapy systemic reaction events

  Subcutaneous immunotherapy systemic reaction events will be graded using the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Each grade is based on organ system involved and severity. Organ systems are defined as cutaneous, conjunctival, upper respiratory, lower respiratory, gastrointestinal, cardiovascular and other. A reaction from a single organ system such as cutaneous, conjunctival or upper respiratory, but not asthma, gastrointestinal, or cardiovascular is classified as a grade 1. Symptom(s)/sign(s) from more than 1 organ system or asthma, gastrointestinal, or cardiovascular are classified as grades 2 or 3. Respiratory failure or hypotension with or without loss of consciousness define grade 4 and death grade 5. The grade is determined by the physician's clinical judgement.

  Up to week 11

• Number of participants with specific local reactogenicity events

  Participants will be asked to record local reactogenicity (pain, tenderness, erythema/redness, Induration/Swelling) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (potentially life-threatening).

  Up to week 12

• Number of participants with specific systemic reactogenicity events

  Participants will be asked to record systemic reactogenicity (nausea/vomiting, diarrhea, headache, fatigue, myalgia) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (potentially life-threatening).

  Up to week 12

Secondary Outcomes (2)

• Change from baseline in immunological response to ASP2390 as assessed by HDM allergen-specific IgG4 levels

  Baseline and up to week 24

• Number of participants with Adverse Events

  Up to 5 years

Study Arms (4)

ASP2390 Low Dose (Cohort 1)

EXPERIMENTAL

Participants will receive a low dose of ASP2390 once weekly for a total of 12 doses. After all participants in cohort 1 complete 4 doses of treatment, the overall safety and tolerability of the dose will be evaluated by the Dose Escalation Committee (DEC).

Biological: ASP2390

Placebo Low Dose (Cohort 1)

PLACEBO COMPARATOR

Participants will receive a low dose of matching Placebo once weekly for a total of 12 doses.

Biological: Placebo

ASP2390 High Dose (Cohort 2)

EXPERIMENTAL

Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.

Biological: ASP2390

Placebo High Dose (Cohort 2)

PLACEBO COMPARATOR

Participants will receive a high dose of matching Placebo once weekly for a total of 12 doses.

Biological: Placebo

Interventions

ASP2390 BIOLOGICAL

Intradermal

ASP2390 High Dose (Cohort 2); ASP2390 Low Dose (Cohort 1)

Placebo BIOLOGICAL

Intradermal; normal saline solution

Placebo High Dose (Cohort 2); Placebo Low Dose (Cohort 1)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has a history of house dust mite (HDM) induced allergic rhinitis with or without conjunctivitis of 1 year or longer in duration at screening 1.
• Subject has positive skin prick test (SPT) to D. pteronyssinus.
• Subject has a serum specific immunoglobulin E (IgE) level to D. pteronyssinus at screening 1 or within the past 12 months (if performed and documented at the clinical unit).
• Subject shows a positive symptomatic reaction to an HDM based on total nasal symptom score (TNSS) during the challenge test at screening 2.
• Subject has a forced expiratory volume in 1 second (FEV1) of 80% of predicted value or greater at screening 1.
• Subject has a body mass index (BMI) range of 18.5 to 35.0 kg/m2, inclusive and weighs at least 50 kg at screening 1.
• A female subject is eligible to participate if the female subject is not pregnant and at least 1 of the following conditions applies:
• Not a woman of childbearing potential (WOCBP), OR
• WOCBP who agrees to follow the contraceptive guidance starting at screening 1 and throughout the initial safety follow-up period.
• Female subject must agree not to breastfeed starting at screening 1 and throughout the initial safety follow-up period.
• Female subject must not donate ova starting at screening 1 and throughout the initial safety follow-up period.
• A male subject with female partner(s) of childbearing potential must agree to use contraception until after completion of the initial safety follow-up period.
• A male subject must not donate sperm until after completion of the initial safety follow-up period.
• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner(s) is(are) breastfeeding until after completion of the initial safety follow-up period.
• Subject agrees not to participate in another interventional study while receiving study drug in present study and until after completion of the initial safety follow-up period.

You may not qualify if:

• Subject with concomitant allergies to seasonal aeroallergens which are anticipated to be or become active through the completion of the week 18 daily symptom diary.
• Subject with a concomitant allergy to an animal dander who has exposure on a regular basis to the respective animal dander.
• Subject has received immunosuppressive treatment within 3 months prior to screening 1.
• Subject has received previous immunotherapy treatment with any HDM allergen within 3 years prior to screening 1.
• Subject is receiving ongoing treatment with any specific immunotherapy for other allergies or plans to receive during the course of the primary study period.
• Subject who has used systemic (or inhaled) steroid, mast cell stabilizing drug, T-helper cell type 2 (Th2) cytokine inhibitor, thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist, β-blocker, α-adrenergic blockers, ergot alkaloids, angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers within 2 months prior to first study drug administration.
• Subject who has used biologics that are immune modulators within 3 months prior to first study drug administration.
• Subject who has received or is planning to receive vaccination of a live vaccine within 28 days prior to the first administration of the study drug and/or subject who has received or is planning to receive vaccination of an inactive vaccine/toxoid within 7 days prior to the first administration of the study drug during the primary study period.
• Subject with mild to severe asthma receiving therapy.
• Subject has a nasal condition that could confound the efficacy or safety assessments.
• Subject who has history of allergic reactions such as anaphylactic shock, exanthema generalized, angioedema or hypotension caused by HDM and/or any medical products (including vaccine) in the past.
• Subject who has immune disorders and/or diseases requiring immunosuppressive drugs.
• Subject who was diagnosed with immunodeficiency in the past.
• Subject who is unable to discontinue antihistamines.
• Subject has received investigational study drug within 28 days or 5 half-lives, whichever is longer, prior to screening 1.

Sponsors & Collaborators

• Astellas Pharma Global Development, Inc.: lead

Study Sites (2)

Site DE49001

Berlin, Germany

Location

Site DE49002

Hanover, Germany

Location

Study Officials

• Senior Medical Director

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2019
• First Posted: December 4, 2019
• Study Start: September 9, 2020
• Primary Completion: December 22, 2022
• Study Completion (Estimated): December 31, 2026
• Last Updated: May 29, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)